文献速递产科母胎医学

乙胺嘧啶联合磺胺嘧啶与螺旋霉素产前治疗减少弓形虫病胎盘传播的多中心随机试验

Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial.
PubMed 文献 · Am J Obstet Gynecol · 2018-06-02

在法国36个中心开展的随机开放标签试验中,143名弓形虫病血清阳转孕妇分别接受乙胺嘧啶联合磺胺嘧啶或螺旋霉素治疗。乙胺嘧啶联合磺胺嘧啶组胎儿脑部超声异常0/73例,低于螺旋霉素组的6/70例(P=0.01);传播率两组分别为18.5%和30%,差异未达统计学显著(P=0.147)。

要点

  • 乙胺嘧啶联合磺胺嘧啶组胎儿脑部超声异常0/73例,螺旋霉素组6/70例(P=0.01)。
  • 传播率乙胺嘧啶联合磺胺嘧啶组18.5%(12/65) vs 螺旋霉素组30%(18/60),P=0.147。
  • 两组各有1名孕妇出现严重皮疹,均发生于乙胺嘧啶联合磺胺嘧啶组。

核心结论

  • 乙胺嘧啶联合磺胺嘧啶组的传播率有低于螺旋霉素组的趋势,但未达统计学显著,可能因入组提前终止导致统计效能不足。
  • 乙胺嘧啶联合磺胺嘧啶组未出现胎儿脑部弓形虫病病灶。
  • 这些有希望的结果鼓励进一步研究化学预防以预防先天性弓形虫病。

研究设计与样本

  • 随机开放标签试验,在法国36个中心开展,比较乙胺嘧啶(50 mg每日一次)联合磺胺嘧啶(1 g每日三次)加亚叶酸与螺旋霉素(1 g每日三次)在弓形虫病血清阳转后的疗效与耐受性。
  • 2010年11月至2014年1月共随机分配143名女性。
  • 131例 later 进行了羊膜穿刺,其中乙胺嘧啶联合磺胺嘧啶组67例中7例(10.4%)弓形虫聚合酶链反应阳性,螺旋霉素组64例中13例(20.3%)阳性。

主要发现

  • 胎儿脑部超声异常在乙胺嘧啶联合磺胺嘧啶组为0/73例,螺旋霉素组为6/70例(P=0.01),其中2例妊娠终止。
  • 排除18名状态未明确的儿童后,传播率乙胺嘧啶联合磺胺嘧啶组为12/65(18.5%),螺旋霉素组为18/60(30%),P=0.147,比值比为0.53(95%置信区间0.23-1.22)。
  • 校正后,在血清阳转后3周内开始治疗时交互作用P=0.03,趋势更强(95%置信区间0.00-1.63)。
  • 2名女性出现严重皮疹,均发生于乙胺嘧啶联合磺胺嘧啶组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 存在传播率降低的趋势但未达统计学显著,可能因入组提前终止导致统计效能不足。
  • 这些有希望的结果鼓励进一步研究化学预防以预防先天性弓形虫病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of prophylaxis to prevent prenatal toxoplasmosis transmission is controversial, without any previous randomized clinical trial. In France, spiramycin is usually prescribed for maternal seroconversions. A more potent pyrimethamine + sulfadiazine regimen is used to treat congenital toxoplasmosis and is offered in some countries as prophylaxis. OBJECTIVE: We sought to compare the efficacy and tolerance of pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission. STUDY DESIGN: This was a randomized, open-label trial in 36 French centers, comparing pyrimethamine (50 mg qd) + sulfadiazine (1 g tid) with folinic acid vs spiramycin (1 g tid) following toxoplasmosis seroconversion. RESULTS: In all, 143 women were randomized from November 2010 through January 2014. An amniocentesis was later performed in 131 cases, with a positive Toxoplasma gondii polymerase chain reaction in 7/67 (10.4%) in the pyrimethamine + sulfadiazine group vs 13/64 (20.3%) in the spiramycin group. Cerebral ultrasound anomalies appeared in 0/73 fetuses in the pyrimethamine + sulfadiazine group, vs 6/70 in the spiramycin group (P = .01). Two of these pregnancies were terminated. Transmission rates, excluding 18 children with undefined status, were 12/65 in the pyrimethamine + sulfadiazine group (18.5%), vs 18/60 in the spiramycin group (30%, P = .147), equivalent to an odds ratio of 0.53 (95% confidence interval, 0.23-1.22) and which after adjustment tended to be stronger (P = .03 for interaction) when treatment started within 3 weeks of seroconversion (95% confidence interval, 0.00-1.63). Two women had severe rashes, both with pyrimethamine + sulfadiazine. CONCLUSION: There was a trend toward lower transmission with pyrimethamine + sulfadiazine, but it did not reach statistical significance, possibly for lack of statistical power because enrollment was discontinued. There were also no fetal cerebral toxoplasmosis lesions in the pyrimethamine + sulfadiazine group. These promising results encourage further research on chemoprophylaxis to prevent congenital toxoplasmosis.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018. PMID: 29870736. doi:10.1016/j.ajog.2018.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。